non-alcoholic fatty liver. Fatty ( change of ) liver , not elsewhere classified
Conditions
Interventions
Intervention 1: intervention group :Extra Virgin Olive Oil, 20% of total daily energy requirement olive will be replaced with usual daily consumption of oil for every patients for 12 weeks. Interventi
Treatment - Other
intervention group :Extra Virgin Olive Oil, 20% of total daily energy requirement olive will be replaced with usual daily consumption of oil for every patients for 12 weeks
control group :( not application )20% of total daily energy requirement from usual daily consumption of oil for 12 weeks
Sponsors
Vice-chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: signing written informed consent, age between 20and 60, diagnosis of non-alcoholic fatty liver disease by fatty infiltration on ultrasound and abnormal serum liver function tests (AST or ALT>30 u/l in men and >20 in women), no smoking, BMI between 25 to 35, no pregnancy or lactation, no use of dietary supplements 2 month prior to enrollment, not having diabetes, , acute heart disease, , other form of liver disease (viral or autoimmune hepatitis, metabolic and hereditary liver disease), no usual use of Olive Oil in dietary pattern, no use of drugs that induces steatosis (amidarone, methotrexate, systemic glucocorticoid, tetracycline, tamoxifen, estrogen, anabolic steroids, valporic acid) , no use of Lipid lowering drugs . Exclusion Criteria: those who are not interested in participating in the study, start using drugs affecting liver functiont, failure to complete or correct use of Olive Oil according to the instruction given , change in recommended diet and daily physical activity
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ALT. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: IFCC,IU/D.;Sserum AST. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: IFCC,IU/D.;Steatosis severity. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| TNF a. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: ELISA5,Pg/L.;Fasting TG. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: enzymetic method , mg / dl.;Insulin resistance. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: calculation.;Fasting insulin. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: Immunoassay radiometer,?U / ml.;FastingGlucose. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: Colorimetric method.mg / dl.;HDL - C. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: enzymetic method , mg / dl.;LDL - C. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: enzymetic method , mg / dl.;Total cholestrol. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: enzymetic method , mg / dl.;Percent body weight. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: Caliper, percent.;BMI. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: calculation,Kg / m2.;Waist circumference. Timepoint: BEFORE AND END OF INTERVENTION. Method of measurement: TAPE , Cm. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Farzad Shidfar
Faculty of Public Health of Tehran University of Medical Sciences
Outcome results
None listed